Event: Ingersoll Rand will release 2Q26 results after the market close on Thursday, July 30, 2026; its earnings call is scheduled for Friday, July 31 at 8:00 a.m. ET. The central issue is less the reported EPS print than whether IR validates the inflection embedded in its full-year outlook: improving short-cycle demand, resumed growth in long-cycle order conversion, and a meaningful second-half step-up in IT&S margins.
IR enters 2Q with a credible operational setup but a relatively demanding need to demonstrate execution. Management’s last explicit quarter-level framing called for:
The most important read-through will be whether the company can show that the modest short-cycle improvement seen in 1Q and reiterated in June is now reaching consolidated organic growth—without another deterioration in the core Industrial Technologies & Services (IT&S) margin.
IR shares closed July 29 at $84.46, up roughly 4.5% from July 1 and about 4.0% from the April 28 pre-1Q-results close. That suggests investors have regained some confidence in the second-half setup, increasing the importance of demand, margin, and guidance commentary.
IR reaffirmed full-year 2026 guidance after 1Q:
| Full-year 2026 guidance | Management outlook |
|---|---|
| Revenue growth | 2.5%–4.5% |
| Organic revenue growth | 0%–2% |
| M&A contribution | ~2% |
| FX contribution | ~0.5% |
| Adjusted EBITDA | $2.13B–$2.19B |
| Adjusted EPS | $3.45–$3.57 |
| FCF conversion | ~95% of adjusted net income |
| Revenue / EBITDA / EPS phasing | 48% / 46% / 46% in 1H, respectively |
Using the company’s 2025 revenue base and its stated first-half phasing, the framework implies roughly $1.92B–$1.99B of 2Q revenue. Similarly, simple EBITDA and EPS phasing produces approximately $511M–$538M of adjusted EBITDA and $0.82–$0.87 of adjusted EPS for 2Q. These are guidance-derived ranges rather than sell-side consensus estimates and should be treated as directional because the company’s phasing percentages are rounded.
Management’s more useful qualitative guide is clearer: company organic growth should be around flat to slightly positive in 2Q, while EBITDA margin remains down year over year—particularly in IT&S—before recovering more materially in the back half.
IR’s 1Q results were solid on reported growth and earnings, but the composition was mixed:
| 1Q26 metric | Result | YoY change |
|---|---|---|
| Revenue | $1.847B | +8% reported |
| Organic revenue growth | (0.3%) | — |
| Orders | $1.978B | +5% reported |
| Organic orders growth | (1.9%) | — |
| Book-to-bill | 1.07x | — |
| Adjusted EBITDA | $469M | +2% |
| Adjusted EBITDA margin | 25.4% | (140) bps |
| Adjusted EPS | $0.77 | +7% |
| Free cash flow | $163M | (27%) |
The key tension was concentrated in IT&S: 1Q organic orders fell 3% and organic revenue fell 2%, while its 26.7% EBITDA margin declined 210 bps. Management attributed the pressure to lower organic volume flow-through, tariff-related pricing that offset dollar costs but diluted margins, and ongoing commercial investment.
By contrast, Precision & Science Technologies (P&ST) was the clear positive: organic revenue grew 4%, and adjusted EBITDA margin expanded 120 bps to 30.3%.
Management’s 1Q call highlighted improving short-cycle trends in U.S. compressors, core tools, precision technologies, blowers, and vacuum. At its June 10 conference appearance, IR said those trends had continued to normalize and that the business was no longer carrying the discrete China, EV-battery, and RNG-related headwinds that had complicated prior periods.
Investors will want evidence in:
This matters because approximately 40% of revenue is aftermarket, while roughly three-quarters of original-equipment revenue is short- to medium-cycle. Better activity in those businesses should move into revenue relatively quickly—typically within roughly 30–90 days, according to management.
What would be constructive: positive organic orders, a book-to-bill above 1x, and commentary that short-cycle growth broadened beyond a few product categories.
What would concern investors: another quarter in which management describes improving underlying activity but consolidated organic orders/revenue remain negative because growth is not broad enough to overcome long-cycle timing.
This is likely the largest stock-moving issue.
Management specifically framed 2Q company EBITDA margin as 50–100 bps lower year over year, but sequentially better than 1Q. The company expects IT&S margins to improve more visibly in 2H, driven by:
The issue is credibility and timing. IT&S margins have been pressured for several quarters, and investors will likely focus on whether 2Q results show tangible evidence that the bridge to 2H is intact.
For reference, IT&S produced a 28.6% adjusted EBITDA margin in 2Q25. A 50–100 bp company-level decline implies a 2Q26 margin framework around the mid-26% range at the consolidated level, though segment mix and corporate costs will matter.
The preferred outcome: margins improve sequentially, management reaffirms the back-half ramp, and the explanation is supported by evidence that productivity, price/cost, and volume are behaving as expected.
The risk outcome: margins fall more than anticipated or management needs to push the recovery further into 4Q, which would put the full-year EBITDA guide under greater scrutiny.
P&ST is increasingly important to the company’s quality-of-growth narrative. The segment delivered 4% organic revenue growth and 30.3% EBITDA margin in 1Q, with particular strength in Life Science Technologies.
The Life Sciences portfolio is now roughly a $600M–$700M business, including legacy medical technologies, ILC Dover’s biopharma operations, medical-device components, and a smaller space-related business. Management described biopharma as the strongest current contributor, supported by single-use containment, high-potency APIs, GLP-1-related applications, and broader pharmaceutical capacity investment.
Key 2Q indicators:
A resilient P&ST print could help offset a still-muted IT&S quarter and support confidence in the broader 2H growth algorithm.
In 1Q, IR cited approximately $40M of delayed orders, mainly tied to long-cycle Middle East projects. Management said roughly one-third had returned in April and has consistently characterized the issue as timing rather than cancellation.
This remains important because long-cycle orders feed backlog and help support the second-half and 2027 revenue outlook. IR has described its long-cycle funnel as healthy, albeit with slower customer decision-making and an elongated RFQ-to-order process.
Investors should look for:
The latter is a potential upside option rather than a near-term forecast: management has noted that compressors can represent a significant portion of manufacturing-facility energy use, and sustained high energy prices can improve the customer payback case for replacement equipment.
M&A is core to the IR equity story. Management is targeting 400–500 bps of annualized acquired revenue in 2026 and entered 2Q with more than 200 companies in its funnel and 10 transactions at the letter-of-intent stage. It also closed several smaller deals year to date, including the Fox acquisition in dosing-pump-related technology.
The June update suggested the pipeline remained active and balanced across IT&S and P&ST, with emphasis on routine bolt-ons rather than a near-term repeat of the scale of ILC Dover.
Items to monitor:
A modest revenue or EPS beat likely will not be sufficient on its own. The market will assess whether IR can maintain the three key assumptions embedded in its full-year outlook:
A maintained full-year guide would be the expected result if 2Q organic growth is around flat, margins improve sequentially, and management reiterates confidence in its 2H drivers. This would keep attention on the implied acceleration rather than eliminate skepticism around it.
The most constructive setup would combine positive organic orders, improving IT&S margin trajectory, sustained P&ST strength, and confirmation that delayed Middle East orders are returning. A guidance increase is possible but not necessary for a favorable market reaction if the evidence supporting the existing outlook becomes more convincing.
The clearest downside would be another miss in IT&S margins, a lack of conversion in long-cycle projects, or signs that short-cycle “stabilization” is not yet broad enough to support the expected 2H growth. Any reduction to the 2026 guide—or even a maintained guide paired with materially more cautious margin language—would likely be poorly received.
IR’s 2Q26 report is a validation quarter. The company does not need a dramatic demand surge to support its outlook; it needs to demonstrate that its expected progression is occurring:
A clean print would reinforce the view that 1Q was the trough for organic growth and margin pressure. Conversely, weak IT&S profitability or softer-than-expected order conversion would challenge the central assumption behind the current full-year guide: that operational momentum meaningfully improves in the second half.